 Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Orforglipron for Sale > Orforglipron2212020-52-3 99%Purity

Orforglipron2212020-52-3 99%Purity

Name: Orforglipron2212020-52-3 99%Purity
Brand: fullas
SKU: pr2602011067
Price: 100 USD
Availability: InStock

29 Inquiries

Unit Price: Get Latest Price 

CAS No.:

2212020-52-3

Grade:

Pharmaceutical Grade

Content:

99%

Port:

hangzhou

Brand:

fullas

Packaging:

1g/bag

Price valid (until):

2026-03-01

Contact Supplier

 Chat Now

Hangzhou Fullas Pharmatech Co.,Ltd.

Company Type:

Distributor

Location:

China

Payment Terms:

TT against copy of documents,L/C,TT against B/L draft before shipment

Average Lead Time:

1 days

Qualification:

Main Products:

GLP-1,Tirzepatide,Retatrutide,MOTS-c

 Visit Store

Product Details
Seller Information
Inquiry History

Description

Product Detail

Pls input...

Items

Specifications

Orforglipron is the first oral small-molecule GLP-1 receptor agonist to successfully complete a Phase 3 clinical trial. It can be administered at any time of day without dietary or water intake restrictions, offering greater convenience for patients and potentially improving medication adherence compared to injectable GLP-1 formulations.

As a pioneering agent in oral GLP-1 drug development, Orforglipron is poised to be the first in its class to receive regulatory approval, positioning it to capture substantial market share. In the pivotal Phase 3 ACHIEVE-1 trial, Orforglipron demonstrated robust efficacy across all dose groups, with reductions in glycated hemoglobin (HbA1c) ranging from 1.3% to 1.6%. At the highest once-daily dose, participants achieved an average weight loss of 7.3 kg, representing a 7.9% reduction in body weight. The overall safety and tolerability profile of Orforglipron was consistent with that of injectable GLP-1 receptor agonists, supporting its clinical utility.

The compound patent for Orforglipron is set to expire in May 2039.

ECHEMI Editorial Reference

Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

Basic Info

Product Name:

Orforglipron

Other Name:

1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833

CAS No.:

2212020-52-3

Molecular Formula:

C48H48F2N10O5

InChIKeys:

USUWIEBBBWHKNI-BBGRWQLENA-N

Molecular Weight:

882.97

EC Number:

278-636-5

Color/Form:

Off-white to light yellow

Categories:

Bulk Drug Intermediates

Characteristics

Density:

1.50±0.1 g/cm3(Predicted)

PKA:

7.33±0.20(Predicted)

Critical Temperature & Pressure:

Store at -20°C

See More Orforglipron Properties 

Seller Information

Business Type:
Distributor

Main Products:
GLP-1,Tirzepatide,Retatrutide,MOTS-c

Location:
5 Euro America Financial City EFC Yuhang District Hangzhou China 311100 P.R.China

Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment

Average lead Time:
1 days

Year of Establishment:
2023

Inquiry History

29 Inquiries

Country	Product	Purchase Quantity	Date Posted
Bulgaria	orforglipron	1 KG	Aug 27, 2025
United Kingdom	Orforglipron	1000 MT	Oct 17, 2026
Austria	Orforglipron	1000 MT	Jun 12, 2026
Switzerland	Orforglipron	10 MG	Apr 25, 2026
United States	Orforglipron	20 G	Apr 3, 2026
United States	Orforglipron	10 G	Mar 29, 2026
United States	oforglipron	3 KG	Jul 4, 2025
United Kingdom	Orforglipron	1 G	Jul 9, 2026
Belgium	Orforglipron	1 G	Jun 14, 2026
Puerto Rico	Orforglipron	1 G	Mar 2, 2026
United States	Orforglipron	10 G	Oct 24, 2025
United States	Orforglipron	1 G	Sep 30, 2025
United States	Orforglipron	1 G	Sep 26, 2025
United States	Orforglipron	1 G	Sep 26, 2025
United States	orforglipron	1 MT	Sep 20, 2025
United States	Orforglipron	1 KG	Apr 18, 2025
Canada	LY-3502970	10 G	Feb 26, 2026
Switzerland	Orforglipron	100 G	Sep 25, 2026
India	orforglipron	1.00 G	Jul 16, 2026
United States	orforglipron	10 G	Apr 20, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Orforglipron (high qualified)	/	$1-1.2/KG FOB	Hangzhou zhongqi chem co.,Ltd	Inquiry
High Quality Orforglipron 99% powder 2212020-52-3 Shaanxi Dideu Medichem Co.Ltd	Chemical Grade/99	$1/G FOB	Shaanxi Dideu Medichem Co. Ltd	Inquiry
Orforglipron LY3502970 receptor agonist 1 2212020-52-3	Pharmacy Grade/99	$90-110/G FOB	Dingwang Technology (Wuhan) Co., Ltd.	Inquiry
Weight Loss 99% Orforglipron/LY3502970/LY-3502970 CAS: 2212020-52-3 Best Quality	Pharmaceutical Grade/99.9	$90-115/G FOB	Hangzhou Hyper Chemicals Limited	Inquiry
2212020-52-3 Orforglipron-LY3502970	/99	$5-6/KG FOB	Conier Chem&Pharma Limited	Inquiry

Orforglipron2212020-52-3 99%Purity

Product Details

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches

More from this Seller